Home » Stocks » AZYO

Aziyo Biologics, Inc. (AZYO)

Stock Price: $16.00 USD 0.70 (4.58%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 156.46M
Revenue (ttm) 41.63M
Net Income (ttm) -15.63M
Shares Out 10.23M
EPS (ttm) -1.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $16.00
Previous Close $15.30
Change ($) 0.70
Change (%) 4.58%
Day's Open 15.39
Day's Range 14.48 - 16.42
Day's Volume 26,970
52-Week Range 10.77 - 16.42

News

Hide News
GlobeNewsWire - 2 months ago

SILVER SPRING, Md., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differen...

GlobeNewsWire - 2 months ago

SILVER SPRING, Md., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differen...

About AZYO

Aziyo Biologics, a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo, a biological envelope that remodels into vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic devices; and ProxiCor, Tyke, and VasCure, which are a portfolio of extracellular matrices that retain the natural composition of colla... [Read more...]

Industry
Medical Devices
IPO Date
Oct 8, 2020
CEO
Ronald K. Lloyd
Employees
156
Stock Exchange
NASDAQ
Ticker Symbol
AZYO
Full Company Profile

Financial Performance

In 2019, AZYO's revenue was $42.90 million, an increase of 9.90% compared to the previous year's $39.04 million. Losses were -$11.94 million, 3.22% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for AZYO stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 25.00% from the latest price.

Price Target
$20.00
(25.00% upside)
Analyst Consensus: Strong Buy